Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 1997

View Archived Issues

NK1 antagonist effective in rat model of focal cerebral ischemia

Attenuation of cyclophosphamide-induced bladder damage in animals by GR-203040

Inflazyme contracts Inveresk Research for IND support

New orally active immunosuppressant for combination with ciclosporin

Additional results for Bradycor in traumatic brain injury

Kosan receives NIH grant for macrolide antibiotic development

Schering-Plough seeks approval for pediatric indication of Intron A

Novastan granted priority review status by FDA

Preliminary results reported for RMP-7/carboplatin

Promising phase II results for Genzyme Transgenics' rhATIII

Pharmacia & Upjohn's urinary incontinence treatment approved in Sweden

Agents useful for BPH from Pfizer

Warner-Lambert/CoCensys develop neuroprotective agents

Osteoprotegerin: new polypeptide for bone diseases

Ribi seeks approval for melanoma vaccine in Canada

Ethnic differences in codeine's efficacy/side effects

Copaxone approved in Canada

SB-204269, an anticonvulsant with a unique mechanism of action

Resveratrol found in edible peanuts

RPR submits NDA for novel antibiotic

Nepicastat: a novel dopamine-beta-hydroxylase inhibitor for CHF

GSH prevents cisplatin-induced toxicity

Treatment for preleukemic disorder from Milkhaus enters phase III

Effects of AE-0047 on lipid profiles

CDR Therapeutics and CellGenEx merge to form Xcyte Therapies

(S)-(-)-OSU-6162 effective in monkey model of Parkinson's disease

Tolmetin eyedrop formulation evaluated in rabbits

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...